关于 "Cytoskeleton & Motor Proteins" 的结果189+ 个结果

  • GC20211 structure
    Protein A Agarose (Fast Flow)

    Protein A Agarose (Fast Flow)主要用于免疫沉淀(Immunoprecipitation,IP)或免疫共沉淀(Co-IP),也可以用于抗体的纯化。

  • GC20212 structure
    Protein G Agarose (Fast Flow)

    Protein G Agarose (Fast Flow)主要用于免疫沉淀(Immunoprecipitation,IP)或免疫共沉淀(Co-IP),也可以用于抗体的纯化。

  • GC26555 structure
    GST-tag Protein Purification Kit

    GST标签蛋白纯化试剂盒(GST-tag Protein Purification Kit),俗称GST柱试剂盒,是一种采用了新型的GST-tag Purification Resin,并能简单、快速、高效并且高特异性地纯化GST标签蛋白的试剂盒。

  • GC26821 structure
    APOC2 Protein, Human (His, solution)

    APOC2 蛋白, Human (His) 在 E. coli 中表达,C 端带有6*His 标签。

  • GA20181 structure
  • GA20182 structure
    (Gln²²)-Amyloid β-Protein (1-40)
    CAS: 144410-00-4

    The Dutch mutation (E22Q) of amyloid β-peptide aggregates more readily than the wild-type peptide and the resulting fibrils show increased neurotoxicity. The mutant peptide E22Q induced apoptosis of cerebral endothelial cells at a concentration of 25 μm, whereas WT Aβ 1-40 and the Italian mutant E22K (H-6698) showed no effect.

  • GA20183 structure
    (Gln²²)-Amyloid β-Protein (1-42)
    CAS: 147335-12-4

    The Dutch mutation (E22Q) aggregates more readily than the wild-type sequence. The resulting fibrils show increased neurotoxicity.

  • GA20186 structure
  • GA20197 structure
    (Gly²¹)-Amyloid β-Protein (1-40)
    CAS: 154362-03-5

    Contrary to β-amyloid peptides mutated at position 22 (Dutch, Italian, Arctic mutants) the Flemish mutation (A21G) shows a decreased tendency to aggregate and a reduced neurotoxicity. In the studies of Betts and Tsubuki, A21G was degraded significantly more slowly by neprilysin than the wild-type Aβ 1-40 and the E22 mutants. The relative resistance to proteolytic degradation may account for the pathogenicity of the Aβ mutant.

  • GA20198 structure
    (Gly²¹)-Amyloid β-Protein (1-42)
    CAS: 383200-53-1

    The Flemish mutation (A21G) shows a decreased tendency to aggregate and a reduced neurotoxicity. A21G is pathogenic as it is degraded significantly more slowly by neprilysin than WT Abeta42.

  • GA20199 structure
    (Gly²²)-Amyloid β-Protein (1-40)
    CAS: 175010-18-1

    The highly neurotoxic arctic mutant (E22G) of Aβ has been used to study the mechanisms underlying the formation of soluble and insoluble β-amyloid aggregates. As the wild-type Aβ, the arctic mutant preferably assembles in the presence of GM1 ganglioside.

  • GA20200 structure
    (Gly²²)-Amyloid β-Protein (1-42)
    CAS: 1802086-23-2

    The arctic mutant of amyloid β peptide 1-42, in which Glu²² is substituted by Gly, is distinctly more amyloidogenic than the wild-type Aβ 1-42.

  • GA20242 structure
    (Lys¹⁵)-Amyloid β-Protein (15-21)
    CAS: 190775-14-5

    KKLVFFA contains the KLVFF sequence, which is the minimum sequence binding the full-length amyloid β-protein. It showed improved water solubility compared with KLVFF (H-3682). It can be used as a labeled probe for screening defined sequences in the full-length amyloid β-protein.

  • GA20244 structure
    (Lys²²)-Amyloid β-Protein (1-40)
    CAS: 302905-01-7

    The Italian mutation of β-amyloid 1-40 (E22K) aggregates more rapidly than the wild-type sequence 1-40. It showed increased neurotoxicity, which (according to a solid-phase NMR-study of Masuda et al.) may be due to the salt bridge formed between Lys²² and Asp²³ in the minor conformer. As the Arctic, Flemish, and Dutch mutants, the Italian mutant is degraded considerably more slowly than wild-type Aβ by neprilysin.

  • GA20245 structure
    (Lys²²)-Amyloid β-Protein (1-42)
    CAS: 383200-59-7

    The Italian mutation (E22K) aggregates more rapidly than the wild-type sequence.

  • GA20259 structure
    (Nle³⁵)-Amyloid β-Protein (1-40)
    CAS: 1802086-31-2

    The reactive thioether of Met³? is crucial for the activity of Aβ 1-40 and Aβ 1-42. Due to the replacement of Met by inert Nle, M35Nle Aβ 1-40 was no longer toxic to cultured hippocampal neurons and had little effect on the level of protein carbonyl residues. The Nle peptide showed the same propensity to aggregate, whereas sulfoxide formation hindered the required conformational transition from random coil to β-sheet.

  • GA20260 structure
    (Nle³⁵)-Amyloid β-Protein (1-42)
    CAS: 1802086-51-6

    The thioether of Met³? plays a critical role in the oxidative stress induced by Aβ 1-42 and its neurotoxicity. The norleucine analog Aβ 1-42 M35Nle forms fibrils morphologically indistinguishable from the ones of the native sequence though lacking their neurotoxicity.

  • GA20282 structure
    (Pyr¹¹)-Amyloid β-Protein (11-40)
    CAS: 192377-94-9

    pEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV, the N-terminally truncated isoform of the amyloid β-protein (Aβ) beginning with a pyroglutamate (Pyr) residue at position 11 was used in experiments studying the generality of fibrillogenesis-related helix formation. Comparing the fibrillogenesis kinetics of many of the most important clinically relevant amyloid β-protein alloforms it could be observed that among these peptides (Pyr¹¹)-amyloid β-protein (11-40) exhibited the greatest retardation of fibrillization rate.

  • GA20283 structure
    (Pyr³)-Amyloid β-Protein (3-40)
    CAS: 161818-04-8

    The pyroglutamate-modified amyloid-β peptides derived from Aβ40 (H-7422) and Aβ42 (H-4796) have gained considerable attention as potential key participants in the pathology of Alzheimer's disease (AD) due to their abundance in AD brain, high aggregation propensity, stability, and cellular toxicity. Aβ40 and 42 can be N-terminally truncated by action of cathepsin B. The cyclization of Glu³ is catalyzed by glutaminyl cyclase. Hence, inhibition of these enzymes could be a therapeutic approach to AD.

  • GA20284 structure
    (Pyr³)-Amyloid β-Protein (3-42)
    CAS: 183449-57-2

    (Pyr³)-Amyloid β-Protein (3-42) was found to be the predominant amyloid β-peptide structure deposited in human brain of Alzheimer's disease and Down's syndrome patients. Therefore, (Pyr³)-Aβ (3-42) is suggested to accumulate in the brain and to trigger the formation of insoluble amyloid β-peptide deposits. Nussbaum et al. studies the Prion-like behaviour and tau-dependent cytotoxicity of the truncated Aβ sequence.

  • GA20309 structure
    (Thr²)-Amyloid β-Protein (1-42)

    A mutation very close to the β-secretase cleavage site of APP. The Icelandic mutation A2T of Aβ42 turned out to be less pathogenic than the native sequence. The precursor APP A673T was the first APP variant discovered in humans reducing the risk of Alzheimer's disease. A2T as well affects γ-secretase cleavage, the mutant was an inefficient substrate in a cell-based assay of the enzyme.